American Association for Cancer Research
crc-23-0289-s22.pdf (143.37 kB)

Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

Download (143.37 kB)
journal contribution
posted on 2023-11-08, 14:20 authored by Alexandra V. Vylegzhanina, Ivan A. Bespalov, Ksenia A. Novototskaya-Vlasova, Brandon M. Hall, Anatoli S. Gleiberman, Han Yu, Olga V. Leontieva, Katerina I. Leonova, Oleg V. Kurnasov, Andrei L. Osterman, Grace K. Dy, Alexey A. Komissarov, Elena Vasilieva, Jeff Gehlhausen, Akiko Iwasaki, Christine B. Ambrosone, Takemasa Tsuji, Junko Matsuzaki, Kunle Odunsi, Ekaterina L. Andrianova, Andrei V. Gudkov

Supplementary Table S10 shows gender-specificity of anti-ORF1p IgG titers among healthy subjects and cancer patients.


Genome Protection, Inc.

HHS | NIH | National Cancer Institute (NCI)



Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues by the mechanisms involving p53 but is frequently derepressed in cancer, suggesting that L1-encoded proteins may act as tumor-associated antigens recognized by the immune system. In this study, we established an immunoassay to detect circulating autoantibodies against L1 proteins in human blood. Using this assay in >2,800 individuals with or without cancer, we observed significantly higher IgG titers against L1-encoded ORF1p and ORF2p in patients with lung, pancreatic, ovarian, esophageal, and liver cancers than in healthy individuals. Remarkably, elevated levels of anti–ORF1p-reactive IgG were observed in patients with cancer with disease stages 1 and 2, indicating that the immune response to L1 antigens can occur in the early phases of carcinogenesis. We concluded that the antibody response against L1 antigens could contribute to the diagnosis and determination of immunoreactivity of tumors among cancer types that frequently escape early detection. The discovery of autoantibodies against antigens encoded by L1 retrotransposons in patients with five poorly curable cancer types has potential implications for the detection of an ongoing carcinogenic process and tumor immunoreactivity.